{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T22:44:03Z","timestamp":1753051443706},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00393-019-0606-y","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T10:41:39Z","timestamp":1550832099000},"page":"203-209","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw"],"prefix":"10.1007","volume":"79","author":[{"given":"E. C.","family":"Schwaneck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Krone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"M\u00fcller-Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Gadeholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"Brands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"606_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J\u00a0Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"606_CR2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a\u00a0growing epidemic. J\u00a0Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"606_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1749-6632.2010.05835.x","volume":"1218","author":"R Landesberg","year":"2011","unstructured":"Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G et al (2011) Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci 1218:62\u201379","journal-title":"Ann N Y Acad Sci"},{"key":"606_CR4","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00784-016-1973-2","volume":"21","author":"SO Hong","year":"2016","unstructured":"Hong SO, Lee CY, Jung J, Kim DY, Walter C, Kwon YD (2016) A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians. Clin Oral Investig 21:1905\u20131911","journal-title":"Clin Oral Investig"},{"key":"606_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bjoms.2015.10.006","volume":"53","author":"F Jarnbring","year":"2015","unstructured":"Jarnbring F, Kashani A, Bjork A, Hoffman T, Krawiec K, Ljungman P et\u00a0al (2015) Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma. Br J Oral Maxillofac Surg 53:1007\u20131011","journal-title":"Br J Oral Maxillofac Surg"},{"key":"606_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5624\/isd.2017.47.1.45","volume":"47","author":"HG Jeong","year":"2017","unstructured":"Jeong HG, Hwang JJ, Lee JH, Kim YH, Na JY, Han SS (2017) Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates. Imaging Sci Dent 47:45\u201350","journal-title":"Imaging Sci Dent"},{"key":"606_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcms.2009.06.005","volume":"38","author":"M Kos","year":"2010","unstructured":"Kos M, Kuebler JF, Luczak K, Engelke W (2010) Bisphosphonate-related osteonecrosis of the jaws: a\u00a0review of 34 cases and evaluation of risk. J\u00a0Craniomaxillofac Surg 38:255\u2013259","journal-title":"J Craniomaxillofac Surg"},{"key":"606_CR8","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","volume":"27","author":"K Vahtsevanos","year":"2009","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG et al (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J\u00a0Clin Oncol 27:5356\u20135362","journal-title":"J Clin Oncol"},{"key":"606_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","volume":"67","author":"MR Allen","year":"2009","unstructured":"Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J\u00a0Oral Maxillofac Surg 67:61\u201370","journal-title":"J Oral Maxillofac Surg"},{"key":"606_CR10","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et\u00a0al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J\u00a0Clin Oncol 23:8580\u20138587","journal-title":"J Clin Oncol"},{"key":"606_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12032-009-9195-y","volume":"27","author":"M Bonomi","year":"2010","unstructured":"Bonomi M, Nortilli R, Molino A, Sava T, Santo A, Caldara A et al (2010) Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a\u00a0long-term retrospective analysis. Med Oncol 27:224\u2013229","journal-title":"Med Oncol"},{"key":"606_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O\u2019ryan FS, Gordon NP, Yang J, Hui RL, Martin D et\u00a0al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J\u00a0Oral Maxillofac Surg 68:243\u2013253","journal-title":"J Oral Maxillofac Surg"},{"key":"606_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1746-160X-6-11","volume":"6","author":"C Walter","year":"2010","unstructured":"Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L et al (2010) Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 6:11","journal-title":"Head Face Med"},{"key":"606_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons","year":"2007","unstructured":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J\u00a0Oral Maxillofac Surg 65:369\u2013376","journal-title":"J Oral Maxillofac Surg"},{"key":"606_CR15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.lfs.2007.08.007","volume":"81","author":"H Monkkonen","year":"2007","unstructured":"Monkkonen H, Ottewell PD, Kuokkanen J, Monkkonen J, Auriola S, Holen I (2007) Zoledronic acid-induced IPP\/ApppI production in vivo. Life Sci 81:1066\u20131070","journal-title":"Life Sci"},{"key":"606_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1476-5381.2009.00160.x","volume":"157","author":"J Raikkonen","year":"2009","unstructured":"Raikkonen J, Crockett JC, Rogers MJ, Monkkonen H, Auriola S, Monkkonen J (2009) Zoledronic acid induces formation of a\u00a0pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 157:427\u2013435","journal-title":"Br J Pharmacol"},{"key":"606_CR17","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1074\/jbc.M412817200","volume":"280","author":"LI Plotkin","year":"2005","unstructured":"Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J\u00a0Biol Chem 280:7317\u20137325","journal-title":"J Biol Chem"},{"key":"606_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","volume":"40","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a\u00a0network meta-analysis. Semin Arthritis Rheum 40:275\u2013284e1\u20132","journal-title":"Semin Arthritis Rheum"},{"key":"606_CR19","first-page":"63","volume":"114","author":"P Poxleitner","year":"2017","unstructured":"Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P (2017) The Prevention of medication-related Osteonecrosis of the jaw. Dtsch Arztebl Int 114:63\u201369","journal-title":"Dtsch Arztebl Int"},{"key":"606_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bone.2005.11.024","volume":"38","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Burlet N (2006) Osteoporosis: a\u00a0still increasing prevalence. Bone 38:4\u20139","journal-title":"Bone"},{"key":"606_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-009-1311-y","volume":"30","author":"JD Ringe","year":"2010","unstructured":"Ringe JD, Doherty JG (2010) Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 30:863\u2013869","journal-title":"Rheumatol Int"},{"key":"606_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/BOR.0000000000000267","volume":"28","author":"M Dougados","year":"2016","unstructured":"Dougados M (2016) Comorbidities in rheumatoid arthritis. Curr Opin Rheumatol 28:282\u2013288","journal-title":"Curr Opin Rheumatol"},{"key":"606_CR23","first-page":"453","volume":"11","author":"J Bieniek","year":"2016","unstructured":"Bieniek J, Wilczynski K, Szewieczek J (2016) Fried frailty phenotype assessment components as applied to geriatric inpatients. Clin Interv Aging 11:453\u2013459","journal-title":"Clin Interv Aging"},{"key":"606_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53\u201361","journal-title":"Rheumatology"},{"key":"606_CR25","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2015-207838","volume":"75","author":"A Richter","year":"2016","unstructured":"Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J et\u00a0al (2016) Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 75:1667\u20131673","journal-title":"Ann Rheum Dis"},{"key":"606_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/ar2404","volume":"10","author":"AL Smitten","year":"2008","unstructured":"Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:45","journal-title":"Arthritis Res Ther"},{"key":"606_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62\u201368","journal-title":"Ann Rheum Dis"},{"key":"606_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1902\/jop.2016.150475","volume":"87","author":"N Pischon","year":"2016","unstructured":"Pischon N, Hoedke D, Kurth S, Lee P, Dommisch H, Steinbrecher A et\u00a0al (2016) Increased periodontal attachment loss in patients with systemic sclerosis. J\u00a0Periodontol 87:763\u2013771","journal-title":"J Periodontol"},{"key":"606_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bjoms.2014.11.008","volume":"53","author":"SN Rogers","year":"2015","unstructured":"Rogers SN, Palmer NO, Lowe D, Randall C (2015) United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. Br J Oral Maxillofac Surg 53:176\u2013182","journal-title":"Br J Oral Maxillofac Surg"},{"key":"606_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/odi.12490","volume":"22","author":"O Fede Di","year":"2016","unstructured":"Di Fede O, Bedogni A, Giancola F, Saia G, Bettini G, Toia F et\u00a0al (2016) BRONJ in patients with rheumatoid arthritis: a\u00a0multicenter case series. Oral Dis 22:543\u2013548","journal-title":"Oral Dis"},{"key":"606_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.joms.2012.07.049","volume":"71","author":"KE Fleisher","year":"2013","unstructured":"Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS (2013) Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J\u00a0Oral Maxillofac Surg 71:513\u2013519","journal-title":"J Oral Maxillofac Surg"},{"key":"606_CR32","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1089\/jwh.2015.5617","volume":"25","author":"CC Wang","year":"2016","unstructured":"Wang CC, Lu HT, Dusetzina SB, Wu CH (2016) The association between long-term bisphosphonate use and the risk of fracture among women aged 50 or older with osteoporosis. J\u00a0Womens Health (larchmt) 25:738\u2013746","journal-title":"J Womens Health (larchmt)"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0606-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-0606-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0606-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T15:12:18Z","timestamp":1583248338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-0606-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-0606-y","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"22 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"E.C.\u00a0Schwaneck, O.\u00a0Gadeholt, M.\u00a0Schmalzing, and H.\u2011P.\u00a0Tony have received speaker\u2019s fees, travel grants, research funding, or compensation for consultations or board memberships from Roche, Chugai, MSD, UCB, Baxalta (Shire\/Takeda), CSL Behring, AbbVie, Janssen, Lilly, Pfizer, Celgene, and Novartis. A. Streit, M. Krone, S. Hartmann, U. M\u00fcller-Richter, A.\u00a0C. K\u00fcbler, and R. C. Brands declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}